94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1550081
This article is part of the Research Topic Clinical Pharmacist Service Promotes the Improvement of Medical Quality Volume II View all 46 articles
Differences in Risk Factors for Mortality between T2N1M0 and T3N0M0 Lobular Breast Cancer Patients: A Comparative Study
Provisionally accepted- 1 College of Life Science and Technology, Guangxi University, Nanning, Guangxi Zhuang Region, China
- 2 Weihai Municipal Hospital, Weihai, Shandong Province, China
- 3 The Affiliated Weihai Second Municipal Hospital, Weihai, Shandong Province, China
Objective: This study aimed to explore the differences in risk factors for mortality between T2N1M0 and T3N0M0 lobular breast cancer, and investigate the factors associated with non-lobular breast cancer mortality.Methods: Data from 2,693 T2N1M0 and 1,384 T3N0M0 lobular breast cancer patients from the SEER database (2008-2018) were analyzed. The lobular breast cancer-specific and non-lobular breast cancer mortality were compared using the Kaplan-Meier curve and Log-rank test. The Cox proportional hazards regression analysis was used to determine the risk factors associated with non-lobular breast cancer mortality.The total survival time showed a significant difference between the T2N1M0 and T3N0M0 groups (p=0.0011). Statistically significant difference were found in lung-related disease mortality (p=0.0023), with the survival rate of T2N1M0 higher than that of T3N0M0. Age, surgery, radiotherapy, and chemotherapy were independent factors associated with mortality in lung-related disease patients with both subtypes, and compared with T2N1M0, radiotherapy in T3N0M0 increased the risk of lung-related disease mortality (HR=2.076, 95% CI: 1.4318-3.011).The T3N0M0 group had a higher mortality rate from lung-related diseases compared to the T2N1M0 group, and radiotherapy may increase the risk of lung-related disease death in T3N0M0 patients. These findings provide valuable information for treatment strategies for T2N1M0 and T3N0M0 subtypes of patients and assist physicians and patients make better treatment choices.
Keywords: T2N1M0, T3N0M0, lung-related disease mortality, Radiotherapy, Lobular breast cancer
Received: 22 Dec 2024; Accepted: 20 Feb 2025.
Copyright: © 2025 Xia, Qin, Chen and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Longjie Xia, College of Life Science and Technology, Guangxi University, Nanning, 530004, Guangxi Zhuang Region, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.